- Home
- CEE vs HLVX Comparison
CEE vs HLVX Comparison
Compare CEE & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- HLVX
- Stock Information
- Founded
- CEE 1990
- HLVX 2020
- Country
- CEE Germany
- HLVX United States
- Employees
- CEE N/A
- HLVX 90
- Industry
- CEE Finance Companies
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- HLVX Health Care
- Exchange
- CEE Nasdaq
- HLVX Nasdaq
- Market Cap
- CEE 79.2M
- HLVX 92.6M
- IPO Year
- CEE N/A
- HLVX 2022
- Fundamental
- Price
- CEE $11.97
- HLVX $1.86
- Analyst Decision
- CEE
- HLVX Hold
- Analyst Count
- CEE 0
- HLVX 5
- Target Price
- CEE N/A
- HLVX $2.33
- AVG Volume (30 Days)
- CEE 22.0K
- HLVX 317.3K
- Earning Date
- CEE 01-01-0001
- HLVX 11-07-2024
- Dividend Yield
- CEE 3.86%
- HLVX N/A
- EPS Growth
- CEE N/A
- HLVX N/A
- EPS
- CEE N/A
- HLVX N/A
- Revenue
- CEE N/A
- HLVX N/A
- Revenue This Year
- CEE N/A
- HLVX N/A
- Revenue Next Year
- CEE N/A
- HLVX N/A
- P/E Ratio
- CEE N/A
- HLVX N/A
- Revenue Growth
- CEE N/A
- HLVX N/A
- 52 Week Low
- CEE $7.80
- HLVX $1.55
- 52 Week High
- CEE $10.32
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- CEE 53.41
- HLVX 44.78
- Support Level
- CEE $11.16
- HLVX $1.95
- Resistance Level
- CEE $12.26
- HLVX $1.97
- Average True Range (ATR)
- CEE 0.44
- HLVX 0.07
- MACD
- CEE -0.07
- HLVX -0.02
- Stochastic Oscillator
- CEE 60.45
- HLVX 10.00
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.